H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Metagenomi (MGX) to $7 from $14 and keeps a Buy rating on the shares following the Q4 report. Macroeconomic uncertainties weigh on the genetic medicines field, with reflection in development-stage gene editing stocks, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- Biotech stocks slide as Marks resignation seen being negative for sector
- BMO says Peter Marks resignation ‘significant negative’ for biotech
- Metagenomi Faces Legal Battle Over Alleged Misleading Statements in Moderna Collaboration
- Metagenomi, Inc. Reports 2024 Financial Results and Pipeline Progress
- Metagenomi price target lowered to $20 from $25 at Wells Fargo